Company news from the 09/12/06 News Brief

Share this article:
MedImmune broke ground on a $250 million, multi-phase expansion project at its Frederick, MD, manufacturing site. The expansion will increase MedImmune's manufacturing capacity for monoclonal antibodies including Synagis, which it introduced to the market in 1998 and other products in the company's pipeline.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.